INVOSSA – 変形性関節症治療薬のパイプライン – 市場インサイトと2032年までの予測

Report Overview

KEY INSIGHTS

INVOSSA is a groundbreaking cell and gene therapy designed to treat knee osteoarthritis with a single intra-articular injection. Clinical trials conducted in the United States and globally have demonstrated that INVOSSA can significantly relieve pain, improve mobility, and potentially slow osteoarthritis progression while enhancing joint structure.

As an allogeneic, off-the-shelf therapy, it presents a promising alternative to traditional osteoarthritis treatments and surgeries, potentially postponing the need for multiple surgical procedures. Developed by Kolon TissueGene Inc, Phase II clinical trials in the US showed sustained improvements in pain and function over two years. The company is now preparing for a national Phase III clinical trial in the US to further confirm these results and support the drug’s potential advantages.

Kolon TissueGene Inc, a biopharmaceutical company based in Maryland, the United States, was founded in June 1999. Specializing in the development of cell and gene therapies, the company focuses on treating orthopedic diseases and degenerative disorders. Its therapies are designed to improve quality of life by reducing pain, enhancing function, and slowing disease progression. Over the past 20 years, Kolon TissueGene has developed a unique technology platform aimed at regenerating cartilage, bone, discs, and nerves.

MARKET POTENTIAL AND POSITIONING

INVOSSA is strategically positioned as a groundbreaking cell and gene therapy for knee osteoarthritis (OA), offering a major advancement over traditional treatments. As a first-in-class therapy, it delivers long-lasting pain relief and improved mobility through a single intra-articular injection. Clinical trials in the United States and globally have shown its ability to not only ease symptoms but also potentially slow disease progression and enhance joint structure.

This allogeneic, off-the-shelf therapy presents a less invasive alternative to surgery and conventional treatments, with the potential to delay the need for multiple surgical interventions. Kolon TissueGene’s recent completion of a Phase III trial, along with efforts to secure a disease-modifying osteoarthritis drug (DMOAD) designation from the US FDA, strengthens INVOSSA’s status as a pioneering treatment. Its approval in South Korea and ongoing progress in the United States underscore its global potential and its impact on future OA treatment strategies.

REGIONAL ANALYSIS

Inkwood Research offers an analysis of seven key markets:

• United States
• Germany
• France
• United Kingdom

o Osteoarthritis (OA) is a major public health issue in the United Kingdom, especially with the aging population. According to the National Institute for Healthcare and Excellence (NICE) Clinical Knowledge Summaries, approximately 10 million people in the UK are affected by osteoarthritis, with around 5.4 million specifically experiencing knee osteoarthritis.

o The condition is more common in women than in men and is the leading cause of pain and disability in the UK. Osteoarthritis places a significant burden on those affected, limiting their ability to work, participate in social activities, and maintain a good quality of life.

• Italy
• Spain
• Japan

Table of Contents

1. INTRODUCTION TO THE REPORT
2. INVOSSA OVERVIEW
2.1. PRODUCT DETAIL
2.2. CLINICAL DEVELOPMENT
2.2.1. CLINICAL STUDIES
2.2.2. CLINICAL TRIALS INFORMATION
2.3. OTHER DEVELOPMENTAL ACTIVITIES
2.4. PRODUCT PROFILE
3. COMPETITIVE LANDSCAPE
3.1. MARKETED THERAPIES
3.2. LATE-STAGE EMERGING THERAPIES
4. INVOSSA MARKET ASSESSMENT
4.1. MARKET OUTLOOK OF INVOSSA IN OSTEOARTHRITIS
5. 7 MAJOR MARKET’S ANALYSIS
5.1. MARKET SIZE OF INVOSSA IN THE 7 MAJOR MARKETS FOR OSTEOARTHRITIS
5.2. 7 COUNTRY ANALYSIS
5.2.1. MARKET SIZE OF INVOSSA IN UNITED STATES FOR OSTEOARTHRITIS
5.2.2. MARKET SIZE OF INVOSSA IN GERMANY FOR OSTEOARTHRITIS
5.2.3. MARKET SIZE OF INVOSSA IN FRANCE FOR OSTEOARTHRITIS
5.2.4. MARKET SIZE OF INVOSSA IN ITALY FOR OSTEOARTHRITIS
5.2.5. MARKET SIZE OF INVOSSA IN SPAIN FOR OSTEOARTHRITIS
5.2.6. MARKET SIZE OF INVOSSA IN UNITED KINGDOM FOR OSTEOARTHRITIS
5.2.7. MARKET SIZE OF INVOSSA IN JAPAN FOR OSTEOARTHRITIS
6. SWOT ANALYSIS
7. ANALYST PERSPECTIVE

List of Tables

LIST OF TABLES
TABLE 1: INVOSSA, CLINICAL TRIAL DESCRIPTION, 2024
TABLE 2: INVOSSA, GENERAL DESCRIPTION
TABLE 3: MARKETED THERAPIES
TABLE 4: EMERGING THERAPIES
TABLE 5: INVOSSA MARKET SIZE IN THE 7 MAJOR MARKETS, IN $ MILLION (2019–2032)
TABLE 6: INVOSSA MARKET SIZE IN UNITED STATES, IN $ MILLION (2019–2032)
TABLE 7: INVOSSA MARKET SIZE IN GERMANY, IN $ MILLION (2019–2032)
TABLE 8: INVOSSA MARKET SIZE IN FRANCE, IN $ MILLION (2019–2032)
TABLE 9: INVOSSA MARKET SIZE IN ITALY, IN $ MILLION (2019–2032)
TABLE 10: INVOSSA MARKET SIZE IN SPAIN, IN $ MILLION (2019–2032)
TABLE 11: INVOSSA MARKET SIZE IN UNITED KINGDOM, IN $ MILLION (2019–2032)
TABLE 12: INVOSSA MARKET SIZE IN JAPAN, IN $ MILLION (2019–2032)

List of Figures

LIST OF FIGURES
FIGURE 1: INVOSSA MARKET SIZE IN THE 7 MAJOR MARKETS, IN $ MILLION (2019–2032)
FIGURE 2: INVOSSA MARKET SIZE IN UNITED STATES, IN $ MILLION (2019–2032)
FIGURE 3: INVOSSA MARKET SIZE IN GERMANY, IN $ MILLION (2019–2032)
FIGURE 4: INVOSSA MARKET SIZE IN FRANCE, IN $ MILLION (2019–2032)
FIGURE 5: INVOSSA MARKET SIZE IN ITALY, IN $ MILLION (2019–2032)
FIGURE 6: INVOSSA MARKET SIZE IN SPAIN, IN $ MILLION (2019–2032)
FIGURE 7: INVOSSA MARKET SIZE IN UNITED KINGDOM, IN $ MILLION (2019–2032)
FIGURE 8: INVOSSA MARKET SIZE IN JAPAN, IN $ MILLION (2019–2032)

Inkwood Researchは広範な市場を対象にし、また主要地域/国別の市場調査レポートで世界中の企業に活用されているインドに本社をおく市場調査会社です。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

世界市場レポート

地域別レポート

国別レポート

ご購入に関するご案内

価格・納期について

• 価格
  • 2023年7月より全レポートの価格が値上げされました。弊社ウェブサイトでは旧価格が掲載されているページもございますが、2023年6月以前に出版されたレポートにも値上げが適用されます。予めご了承ください。
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
    • 印刷不可設定のPDFです。
  • コーポレートライセンス
    • 同一企業および関連会社間人数無制限でレポートファイルをご共有可能です。
    • PDF（印刷可能）とExcelをご提供いたします。
• 納期
  • ご注文後3-4営業日以内

• 納品形態
  • Eメール

注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでのご注文をお待ちしております。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

Inkwood Research出版の市場調査レポートに関するご質問やサンプルページのご依頼等はいつでもお気軽にお問合せください。

Inkwood Research 出版レポート一覧